tacrolimus
Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
Cross Reference
Introduction
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
What diseases are associated with tacrolimus?
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Related references are mostly published in these journals:
| Disease | Cross reference | Weighted score | Related literature |
|---|
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with tacrolimus
PubChem Associated disorders and diseases
What pathways are associated with tacrolimus
There are no associated biomedical information in the current reference collection.
PubChem Biomolecular Interactions and Pathways
Link to PubChem Biomolecular Interactions and PathwaysWhat cellular locations are associated with tacrolimus?
Visualization in cellular structure
Associated locations are in red color. Not associated locations are in black.
Related references are published most in these journals:
| Location | Cross reference | Weighted score | Related literatures |
|---|
What functions are associated with tacrolimus?
Related references are published most in these journals:
| Function | Cross reference | Weighted score | Related literatures |
|---|
What lipids are associated with tacrolimus?
Related references are published most in these journals:
| Lipid concept | Cross reference | Weighted score | Related literatures |
|---|
What genes are associated with tacrolimus?
Related references are published most in these journals:
| Gene | Cross reference | Weighted score | Related literatures |
|---|
What common seen animal models are associated with tacrolimus?
There are no associated biomedical information in the current reference collection.
NCBI Entrez Crosslinks
All references with tacrolimus
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Venz S et al. | Contribution of color and power Doppler sonography to the differential diagnosis of acute and chronic rejection, and tacrolimus nephrotoxicity in renal allografts. | 1999 | Transpl. Int. | pmid:10363595 |
| Onsager DR et al. | Efficacy of tacrolimus in the treatment of refractory rejection in heart and lung transplant recipients. | 1999 | J. Heart Lung Transplant. | pmid:10363689 |
| Ito F et al. | FK506 and cyclosporin A inhibit stem cell factor-dependent cell proliferation/survival, while inducing upregulation of c-kit expression in cells of the mast cell line MC/9. | 1999 | Arch. Dermatol. Res. | pmid:10367710 |
| Przepiorka D et al. | Relationship of tacrolimus whole blood levels to efficacy and safety outcomes after unrelated donor marrow transplantation. | 1999 | Biol. Blood Marrow Transplant. | pmid:10371361 |
| Matzinger P | Graft tolerance: a duel of two signals. | 1999 | Nat. Med. | pmid:10371494 |
| Kirk AD et al. | Treatment with humanized monoclonal antibody against CD154 prevents acute renal allograft rejection in nonhuman primates. | 1999 | Nat. Med. | pmid:10371508 |
| Lieberman DN and Mody I | Properties of single NMDA receptor channels in human dentate gyrus granule cells. | 1999 | J. Physiol. (Lond.) | pmid:10373689 |
| Cox KL et al. | Paediatric liver transplantation: indications, timing and medical complications. | 1999 | J. Gastroenterol. Hepatol. | pmid:10382641 |
| Higgins RM et al. | Conversion between cyclosporin and tacrolimus--30-fold dose prediction. | 1999 | Nephrol. Dial. Transplant. | pmid:10383044 |
| Henry ML | Cyclosporine and tacrolimus (FK506): a comparison of efficacy and safety profiles. | 1999 | Clin Transplant | pmid:10383101 |
| Koski GK et al. | Calcium mobilization in human myeloid cells results in acquisition of individual dendritic cell-like characteristics through discrete signaling pathways. | 1999 | J. Immunol. | pmid:10384103 |
| Leung W et al. | Long-term complete remission and immune tolerance after intensive chemotherapy for lymphoproliferative disorders complicating liver transplant. | 1999 | Transplantation | pmid:10385092 |
| Squadrito F et al. | Tacrolimus suppresses tumour necrosis factor-alpha and protects against splanchnic artery occlusion shock. | 1999 | Br. J. Pharmacol. | pmid:10385251 |
| Gerhardt U et al. | Blood pressure control in kidney transplant recipients: influence of immunosuppression. | 1999 | J Auton Pharmacol | pmid:10385269 |
| Liang H et al. | Regulation of angiotensin II-induced phosphorylation of STAT3 in vascular smooth muscle cells. | 1999 | J. Biol. Chem. | pmid:10391929 |
| Hasselder AS | The nursing management of a patient receiving Prograf as a primary immunosuppressive agent. | 1998 Apr-Jun | EDTNA ERCA J | pmid:10392057 |
| Horowitz MM et al. | Tacrolimus vs. cyclosporine immunosuppression: results in advanced-stage disease compared with historical controls treated exclusively with cyclosporine. | 1999 | Biol. Blood Marrow Transplant. | pmid:10392964 |
| Kochi S et al. | Effect of cyclosporin A or tacrolimus on the function of blood-brain barrier cells. | 1999 | Eur. J. Pharmacol. | pmid:10395024 |
| Magee CC et al. | Immunosuppressive agents in organ transplantation. | 1999 | Hosp Med | pmid:10396414 |
| Gold BG et al. | Efficacy of delayed or discontinuous FK506 administrations on nerve regeneration in the rat sciatic nerve crush model: lack of evidence for a conditioning lesion-like effect. | 1999 | Neurosci. Lett. | pmid:10400242 |